polyclon
immunoglobulin
use
sinc
centuri
protect
infecti
agent
toxin
diseas
condit
autoimmun
etiolog
immunoglobulin
prepar
made
pool
select
human
donor
anim
high
titer
antibodi
virus
toxin
antibodi
treatment
provid
passiv
transfer
high
titer
antibodi
either
reduc
risk
reduc
sever
infect
use
prevent
hemolyt
diseas
newborn
modifi
inflammatori
reaction
earlier
drug
nonselect
patient
frequent
succumb
infect
due
suppress
antibodymedi
humor
cellmedi
arm
immun
system
today
princip
approach
alter
lymphocyt
function
use
drug
antibodi
immun
protein
howev
advent
human
organ
tissu
transplant
eg
kidney
heart
bone
marrow
andor
peripher
blood
stem
cell
treatment
option
polyclon
antibodi
therapi
combin
treatment
regimen
use
lower
abil
bodi
immun
system
reject
transplant
howev
use
without
risk
complic
includ
develop
immun
complex
sever
allerg
reaction
summari
polyclon
antibodi
therapi
may
found
tabl
immunosuppress
agent
diseas
modifi
antithymocyt
globulin
rabbit
thymoglobulin
antithymocyt
globulin
equin
atgam
descript
rabbit
antithymocyt
globulin
ratg
equin
antithymocyt
globulin
eatg
purifi
pasteur
prepar
lymphocyt
deplet
polyclon
gamma
immunoglobulin
igg
rais
human
thymu
lymphocyt
rabbit
hors
respect
use
prevent
treatment
renal
transplant
reject
worldwid
histori
antibodi
use
ratg
induct
combin
immunosuppress
therapi
effect
prevent
episod
acut
renal
graft
reject
adult
renal
transplant
recipi
recurr
episod
acut
reject
acut
reject
respons
highdos
corticosteroid
therapi
monoclon
antibodi
prepar
ratg
recipi
lower
incid
biopsyconfirm
acut
reject
episod
greater
eventfre
surviv
year
posttransplant
greater
graft
surviv
year
posttransplant
mechan
action
exact
mechan
polyclon
antibodi
fulli
understood
howev
polyclon
display
specif
toward
wide
varieti
surfac
antigen
ag
express
blymphocyt
dendrit
cell
natur
killer
nk
cell
endotheli
cell
howev
tcell
deplet
consid
play
key
role
modul
express
lymphocyt
surfac
antigen
involv
wide
varieti
function
tcell
activ
endotheli
adher
activ
certain
transcript
factor
interfer
numer
immun
cell
process
cytokin
product
chemotaxi
endocytosi
cell
stimul
prolifer
vitro
studi
indic
bind
eatg
cell
gener
nonspecif
drug
bind
viscer
tissu
includ
thymu
testi
cell
membran
nuclear
cytoplasm
compon
tissu
tonsil
kidney
liver
extens
bound
bone
marrow
cell
peripher
blood
cell
besid
lymphocyt
diseas
treat
mention
earlier
antithymocyt
globulin
use
treatment
prevent
acut
renal
allograft
reject
ratg
recipi
report
achiev
endpoint
success
respons
return
serum
creatinin
level
baselin
end
treatment
within
day
treatment
initi
howev
among
achiev
success
respons
fewer
episod
recurr
reject
occur
ratg
within
day
treatment
cessat
eatg
also
use
treat
moderatetosever
aplast
anemia
patient
unsuit
bone
marrow
transplant
advers
effect
common
advers
effect
fever
thrombocytopenia
leukopenia
gastrointestin
disord
andor
concurr
infect
cytomegaloviru
cmv
infect
gener
higher
ratg
except
highrisk
patient
eatg
therapi
may
result
reactiv
infect
cmv
herp
simplex
viru
epsteinebarr
viru
incid
malign
gener
lower
ratg
therapi
product
made
equin
human
blood
compon
may
carri
risk
transmit
infecti
agent
virus
theoret
creutzfeldtejakob
diseas
cjd
agent
updat
recent
evid
addit
human
antitlymphocyt
globulin
atlg
plu
cyclosporin
methotrex
standard
graftversushost
diseas
gvhd
prophylaxi
prefer
standard
gvhd
prophylaxi
alon
improv
probabl
surviv
without
relaps
chronic
gvhd
myeloabl
peripher
blood
stemcel
transplant
human
leukocyt
antigen
hla
ident
sibl
donor
patient
acut
leukemia
remiss
addit
therapi
provid
better
qualiti
life
shorter
immunosuppress
treatment
compar
standard
gvhd
prophylaxi
without
atlg
antitoxin
immun
globulin
diseas
modifi
tetanu
immun
globulinbaytethypertet
descript
tetanu
immun
globulin
tig
specif
solventdetergenttr
plasmaderiv
product
obtain
donor
immun
tetanu
toxoid
tig
contain
tetanu
antitoxin
provid
temporari
passiv
immun
individu
low
immun
toxin
produc
clostridium
tetani
mechan
action
tig
contain
tetanu
antitoxin
antibodi
neutral
free
form
power
exotoxin
produc
clostridium
tetani
tig
neutral
unbound
exotoxin
affect
toxin
alreadi
bound
nerv
end
diseas
treat
tig
use
provid
passiv
immun
tetanu
part
postexposur
prophylaxi
regimen
follow
injuri
patient
whose
immun
incomplet
uncertain
year
sinc
last
dose
tetanu
toxoid
advers
reaction
slight
sore
inject
site
mild
fever
rare
sensit
repeat
inject
human
immun
globulin
report
antitoxin
immun
globulin
diseas
modifi
cytomegaloviru
immun
globulincytogam
descript
cytomegaloviru
immun
globulin
iv
cmvig
purifi
immun
globulin
hyperimmun
globulin
contain
immunoglobulin
g
igg
deriv
pool
adult
human
plasma
select
high
titer
anticmv
antibodi
mechan
action
cmvig
provid
rel
high
concentr
antibodi
direct
cmv
provid
prophylaxi
cmv
infect
diseas
immunocompromis
individu
result
vitro
studi
mice
indic
anticmv
antibodi
neutral
pathogen
properti
cmv
cmv
usual
target
popul
bone
marrowderiv
myeloid
lineag
progenitor
cell
antibodyneutr
viru
alon
may
enough
prevent
make
activ
diseas
less
sever
alreadi
cmvinfect
individu
diseas
treat
cmvig
provid
passiv
immun
individu
risk
primari
cmv
infectiondiseas
secondari
cmv
diseas
reactiv
cmv
also
prescrib
prophylaxi
cmv
diseas
associ
transplant
kidney
lung
liver
pancrea
heart
except
cmvseroneg
recipi
kidney
cmvseroposit
donor
cmvig
prophylaxi
consid
conjunct
ganciclovir
advers
reaction
frequent
advers
reaction
report
flush
chill
muscl
cramp
back
pain
fever
nausea
vomit
arthralgia
wheez
slight
risk
hemolysi
intraven
immunoglobulin
ivig
product
contain
blood
group
antibodi
may
act
hemolysin
induc
vivo
coat
red
blood
cell
immunoglobulin
caus
posit
direct
antiglobulin
reaction
transfusionrel
acut
lung
injuri
noncardiogen
pulmonari
edema
thrombot
event
report
patient
receiv
ivig
prepar
similar
product
made
human
plasma
cmvig
also
carri
possibl
transmiss
bloodborn
viral
agent
cjd
agent
howev
ivig
treat
solvent
deterg
viral
inactiv
procedur
inactiv
wide
spectrum
lipidenvelop
virus
includ
hepat
b
hepat
c
antivenin
latrodectu
mactan
black
widow
spider
antivenindantivenin
micruru
fulviuseastern
texa
coral
snake
antivenindcrotalida
polyval
immun
fabcrofab
descript
antivenin
steril
nonpyrogen
purifi
lyophil
prepar
specif
venomneutr
serum
globulin
obtain
blood
serum
healthi
hors
expos
venom
black
widow
spider
eastern
coral
snake
micruru
fulviu
venom
respect
contrast
crofab
antivenin
made
ovin
fab
monoval
immunoglobulin
fragment
obtain
blood
healthi
sheep
immun
north
american
crotalina
subfamili
venom
snake
includ
rattlesnak
copperhead
cottonmouth
water
moccasin
mechan
action
mode
action
antivenin
unknown
howev
probabl
act
neutral
venom
black
widow
spider
coral
snake
crofab
venomspecif
fab
fragment
igg
work
bind
neutral
venom
toxin
facilit
redistribut
away
target
tissu
elimin
bodi
diseas
treat
antivenin
indic
patient
symptom
due
bite
black
widow
spider
latrodectu
mactan
bite
two
genera
coral
snake
micruru
includ
eastern
texa
varieti
micruroid
sonoran
arizona
varieti
found
southeastern
arizona
southwestern
new
mexico
antivenin
micruru
fulviu
equin
origin
indic
treatment
manag
adult
pediatr
patient
expos
north
american
crotalid
envenom
advers
effect
immedi
system
reaction
allerg
reaction
anaphylaxi
death
occur
patient
sensit
antivenin
hors
serum
common
advers
reaction
crofab
urticaria
rash
nausea
pruritu
back
pain
high
antibodi
titer
influenza
fresh
frozen
plasma
descript
use
convalesc
person
recov
particular
infect
donor
plasma
high
hemagglutin
inhibit
titer
certain
influenza
strain
recommend
primari
therapi
sever
respiratori
infecti
diseas
includ
influenza
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
histori
antibodi
use
metaanalysi
previou
cohort
studi
influenza
pandem
show
casefat
rate
among
subject
treat
plasma
serum
whole
blood
compar
among
control
similarli
cohort
studi
use
convalesc
plasma
treatment
pandem
influenza
result
mortal
treatment
group
versu
control
group
mechan
action
antiinfluenza
convalesc
plasma
decreas
rate
viral
shed
measur
neutral
antibodi
titer
hemagglutin
inhibit
preexist
immun
previou
infect
vaccin
well
immun
respons
occur
ill
onset
make
mechan
action
complex
diseas
classif
treat
influenza
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
advers
effect
convalesc
plasma
seem
safe
seriou
advers
event
report
relat
underli
influenza
complic
preexist
comorbid
due
convalesc
plasma
usag
descript
antibodi
ebola
viru
ev
whole
blood
plasma
convalesc
donor
may
effect
treatment
ev
infect
histori
antibodi
use
world
health
organ
state
convalesc
blood
plasma
option
treatment
ebola
transfus
local
collect
convalesc
blood
help
decreas
ebola
mortal
therefor
recommend
collect
convalesc
plasma
treat
patient
ebola
viru
infect
mechan
action
fresh
frozen
plasma
ffp
high
titer
antibodi
direct
ebola
viru
advers
effect
convalesc
plasma
seem
safe
advers
effect
digoxin
immun
fabdigifab
digibind
descript
digoxin
immun
fab
steril
purifi
lyophil
monoval
prepar
bovin
immunoglobulin
fab
fragment
bind
digoxin
fab
fragment
obtain
blood
healthi
sheep
immun
digoxin
deriv
digoxindicarboxymethoxylamin
digoxin
analogu
contain
function
essenti
cyclopentaperhydrophenanthren
lacton
ring
moieti
coupl
keyhol
limpet
hemocyanin
final
product
prepar
take
immunoglobulin
fraction
ovin
serum
digest
papain
isol
digoxinspecif
fab
fragment
affin
chromatographi
mechan
action
digifab
digibind
antigenbind
fragment
bind
free
digoxin
molecul
result
equilibrium
shift
away
bind
receptor
therebi
revers
cardiotox
effect
glycosid
subsequ
fabdigoxin
complex
clear
kidney
reticuloendotheli
system
due
papain
treatment
fab
fragment
lack
antigen
determin
fc
fragment
result
reduc
immunogen
patient
oppos
intact
immunoglobulin
product
diseas
treat
digoxin
immun
fab
indic
patient
either
lifethreaten
potenti
lifethreaten
digoxin
toxic
overdos
data
clinic
trial
show
digifab
digibind
reduc
level
free
digoxin
serum
limit
assay
quantit
sever
hour
fab
administr
advers
reaction
digoxin
immun
fab
ovin
gener
well
toler
follow
intraven
iv
administr
hypokalemia
may
occur
sometim
develop
rapidli
patient
receiv
digoxin
immun
fab
ovin
digifab
administ
patient
known
histori
hypersensit
papaya
papain
unless
benefit
outweigh
risk
immun
globulin
antiinfecti
hepat
b
immun
globulinhepagam
bnabihbbayhepbhyperhep
b
sd
descript
hepat
b
immun
globulin
hbig
specif
immun
globulin
hyperimmun
globulin
contain
antibodi
hepat
b
surfac
antigen
antihb
prepar
plasma
healthi
donor
high
titer
antihb
antibodi
provid
temporari
passiv
immun
hepat
b
viru
hbv
hepagamb
solventdetergenttr
steril
solut
purifi
gamma
globulin
contain
antibodi
hb
antigen
contain
high
titer
antihb
plasma
donat
healthi
screen
donor
hbig
hepagamb
manufactur
solventdeterg
sd
treatment
procedur
effect
inactiv
lipidenvelop
virus
hepat
b
viru
hepat
c
viru
human
immunodefici
viru
type
type
howev
sd
less
effect
nonlipidenvelop
virus
hepat
viru
parvoviru
mechan
action
provid
passiv
immun
individu
expos
hepat
b
viru
bind
surfac
antigen
reduc
rate
hepat
b
infect
diseas
treat
hbig
provid
passiv
prophylact
immun
hbv
infect
prevent
perinat
hbv
infect
neonat
born
hb
antigenposit
hbsagposit
mother
postexposur
prophylaxi
suscept
individu
expos
hbv
hbsagposit
materi
eg
blood
plasma
serum
sexual
exposur
hbsagposit
person
household
exposur
person
acut
hbv
infect
prevent
hbv
recurr
liver
transplant
recipi
hbsagposit
hepagamb
hbig
indic
treatment
activ
hepat
b
infect
ineffect
treatment
chronic
activ
hepat
b
infect
advers
reaction
local
advers
reaction
may
occur
site
inject
intramuscular
im
administr
pain
tender
swell
erythema
system
effect
may
occur
im
administr
urticaria
angioedema
nausea
vomit
myalgia
headach
fluor
coldlik
symptom
lightheaded
malais
report
varicella
zoster
immun
globulinvarizig
summari
varicella
zoster
immun
globulin
vzig
specif
immun
globulin
hyperimmun
globulin
vzig
prepar
plasma
donor
select
high
titer
antibodi
varicella
zoster
viru
antivzv
use
provid
temporari
passiv
immun
vzv
mechan
action
vzig
act
neutral
varicella
zoster
viru
via
high
titer
igg
antibodi
present
plasma
use
diseas
treat
vzig
use
postexposur
prophylaxi
varicella
chickenpox
individu
evid
varicella
immun
high
risk
sever
varicella
infect
complic
high
risk
individu
includ
immunocompromis
patient
neonat
whose
mother
sign
symptom
varicella
around
time
deliveri
ie
day
day
prematur
infant
born
week
gestat
expos
neonat
period
whose
mother
evid
immun
prematur
infant
born
week
gestat
weigh
g
birth
expos
neonat
period
regardless
mother
evid
immun
statu
final
pregnant
women
vzig
recommend
outbreak
control
postexposur
treatment
vaccin
avail
children
humor
immunodefici
select
children
hiv
infect
use
vzig
postexposur
prophylaxi
pregnant
women
expos
vzv
may
prevent
reduc
sever
varicella
woman
prevent
fetal
infect
vzig
indic
individu
previous
receiv
ageappropri
varicella
vaccin
subsequ
becam
immunocompromis
diseas
immunosuppress
therapi
later
life
bone
marrow
transplant
recipi
consid
suscept
varicella
regardless
previou
histori
varicella
varicella
vaccin
donor
howev
develop
varicella
herp
zoster
transplant
consid
immun
varicella
advers
reaction
common
advers
effect
report
vzig
clinic
trial
pregnant
women
infant
immunocompromis
adult
children
inject
site
pain
headach
chill
fatigu
rash
nausea
sever
hypersensit
reaction
may
occur
follow
administr
vzig
summari
rimabotulinumtoxin
b
type
b
botulinum
toxin
produc
ferment
bacterium
clostridium
botulinum
type
b
bean
strain
neuromuscular
block
agent
neurotoxin
inhibitor
acetylcholin
releas
motor
nerv
termin
mechan
action
rimabotulinumtoxin
b
botulinum
toxin
serotyp
act
inhibit
acetylcholin
releas
neuromuscular
junction
via
threestep
process
toxin
bind
toxin
intern
inhibit
acetylcholin
releas
neuromuscular
junction
lead
chemic
denerv
flaccid
paralysi
diseas
treat
rimabotulinumtoxin
b
use
manag
adult
cervic
dystonia
also
call
spasmod
torticolli
reduc
sever
abnorm
head
posit
neck
pain
reduct
undesir
excess
contract
striat
smooth
involuntari
muscl
advers
reaction
common
advers
effect
report
botulinum
toxin
dri
mouth
dysphagia
dyspepsia
inject
site
pain
seriou
hypersensit
reaction
rare
report
onabotulinumtoxin
summari
botul
immun
globulin
iv
bigiv
specif
immun
globulin
hyperimmun
globulin
prepar
plasma
adult
volunt
donor
immun
pentaval
botulinum
toxoid
neutral
free
botulinum
toxin
type
b
one
poison
substanc
known
exist
seven
antigen
variant
type
g
mechan
action
bigiv
humanderiv
antitoxin
neutral
botulinum
toxin
bigiv
halflif
approxim
day
vivo
larg
capac
neutral
toxin
diseas
treat
infant
botul
occur
young
infant
ingest
spore
clostridium
botulinum
germin
colon
gi
tract
produc
botulinum
toxin
neurotoxin
caus
gener
weak
loss
muscl
tone
singl
infus
neutral
toxin
least
month
toxin
type
b
may
absorb
colon
infant
younger
year
old
advers
effect
mild
transient
blushlik
erythemat
rash
face
trunk
occur
infant
receiv
bigiv
clinic
studi
rabi
immun
globulinbayrabhyperrab
imogam
rabi
kedrab
descript
rabi
immun
globulin
rig
steril
solut
specif
igg
contain
antibodi
rabi
antigen
use
provid
temporari
passiv
immun
rabi
infect
part
postexposur
prophylaxi
regimen
unvaccin
individu
expos
diseas
viru
mechan
action
rig
humanderiv
antitoxin
neutral
rabi
viru
viru
spread
reduc
infect
pathogen
properti
inhibit
specif
rabi
antibodi
present
rig
neutral
rabi
use
conjunct
rabi
vaccin
administ
seventh
day
first
dose
vaccin
given
rig
provid
immedi
temporari
rabi
virusneutr
antibodi
patient
respond
activ
immun
produc
virusneutr
antibodi
diseas
treat
given
person
suspect
exposur
rabi
one
except
previous
immun
rabi
vaccin
confirm
adequ
rabi
antibodi
titer
receiv
vaccin
advers
reaction
common
local
advers
effect
includ
tender
pain
muscl
sore
stiff
may
occur
site
inject
lowgrad
fever
headach
malais
may
also
occur
immun
globulin
immunomodul
rho
immun
globulinwinrho
rhogam
rhophylac
micrhogam
batrhod
hyperrho
summari
rho
immun
globulin
rhig
consist
antirho
igg
antibodi
red
blood
cell
rho
antigen
rhig
prepar
human
pool
plasma
rho
neg
donor
immun
rho
posit
red
blood
cell
cold
alcohol
fraction
subsequ
purif
infecti
diseas
reduct
technolog
mechan
action
exact
mechan
action
rho
immun
globulin
suppress
format
antirho
fulli
known
treatment
prevent
alloimmun
rhig
bind
rho
antigen
enter
matern
circul
fetalematern
hemorrhag
fmh
involv
rho
posit
fetu
transfus
rho
posit
blood
prevent
stimul
mother
primari
immun
respons
rho
antigen
therefor
prevent
activ
product
antirho
mother
risk
hemolyt
diseas
fetu
newborn
futur
pregnanc
decreas
treatment
idiopath
thrombocytopen
purpura
itp
administr
rho
immun
globulin
rho
posit
individu
believ
caus
transient
mononuclear
macrophag
fc
receptor
fcr
blockad
complex
within
reticuloendotheli
system
particularli
spleen
spare
patient
iggcoat
platelet
fcr
blockad
decreas
fcmediat
phagocytosi
antibodyco
platelet
result
increas
platelet
count
itp
patient
diseas
treat
prevent
alloimmun
dneg
women
childbear
potenti
neonat
weakd
posit
untest
follow
perinat
event
associ
fmh
abort
ectop
pregnanc
amniocentesi
chorion
villu
sampl
extern
cephal
version
abdomin
trauma
antepartum
hemorrhag
also
use
prevent
alloimmun
dneg
individu
receiv
blood
compon
whole
bloodderiv
platelet
apheresi
platelet
andor
granulocyt
similarli
use
treatment
itp
patient
undergon
splenectomi
prepar
rho
immun
globulin
may
administ
im
iv
rhophylac
winrho
sdf
wherea
other
label
im
use
micrhogam
rhogam
hyperrho
sd
full
dose
hyperrho
sd
minidos
use
itp
treatment
rhig
must
administ
iv
advers
reaction
gener
mild
common
headach
fever
chill
pain
inject
site
rare
hypersensit
reaction
degre
hemolysi
inevit
predict
transient
immunoglobulin
gener
bbrand
bivigam
carimun
cuvitru
flebogamma
gammagard
gamastan
gammak
gammaplex
gamunexc
hizentra
hyqvia
octagam
privigen
summari
immun
globulin
im
imig
immun
globulin
iv
ivig
immun
globulin
subcutan
steril
nonpyrogen
prepar
globulin
contain
mani
antibodi
normal
present
adult
human
blood
immun
globulin
ig
collect
either
whole
blood
donat
recov
plasma
apheresi
sourc
plasma
ivig
highli
purifi
product
consist
mostli
igg
halflif
day
hyperimmun
globulin
hyperig
product
manufactur
donor
high
ig
titer
specif
antigen
determin
interest
high
titer
donor
achiev
natur
immun
prophylact
immun
target
immun
hyperig
product
contain
least
fivefoldincreas
titer
compar
standard
prepar
ivig
ivig
product
regul
iuiswho
intern
union
immunolog
societiesworld
health
organ
requir
follow
sourc
materi
must
plasma
obtain
minimum
pool
donor
product
must
free
prekallikrein
activ
kinin
plasmin
preserv
potenti
harm
contamin
iga
content
igg
aggreg
level
need
low
possibl
product
must
contain
least
intact
igg
igg
maintain
opsonin
activ
complement
bind
biolog
activ
igg
subclass
present
similar
proport
normal
pool
plasma
antibodi
level
least
two
speci
bacteria
toxin
two
virus
determin
product
must
demonstr
least
intern
unit
hepat
b
antibodi
per
ml
hepat
radioimmunoassay
titer
least
manufactur
specifi
content
final
product
includ
diluent
addit
chemic
modif
igg
mechan
action
mechan
iginduc
immunomodul
incomplet
understood
includ
macrophag
fc
receptor
blockag
immun
complex
form
ivig
nativ
antibodi
modul
complement
suppress
antibodi
product
suppress
inflammatori
cytokin
chemokin
andor
antiidiotyp
regul
autoreact
blymphocyt
antibodi
ivig
contain
divers
group
antibodi
specif
protect
recipi
multipl
infect
elimin
opson
infecti
organ
via
antibodydepend
cellmedi
cytotox
complement
activ
follow
lysi
neutral
solubl
infecti
protein
immun
complex
format
elimin
re
diseas
treat
ivig
indic
treatment
primari
immun
defici
secondari
immun
defici
itp
kawasaki
diseas
congenit
hypogammaglobulinemia
current
extens
list
diseas
ivig
could
use
also
immunomodulatori
properti
result
increas
list
fdaapprov
nonapprov
indic
imig
use
provid
passiv
immun
hepat
viru
infect
preexposur
postexposur
prophylaxi
suscept
individu
risk
expos
viru
imig
ivig
use
prevent
modifi
symptom
measl
rubeola
suscept
individu
expos
diseas
day
ivig
use
replac
therapi
promot
passiv
immun
patient
primari
humor
immunodefici
unabl
produc
suffici
amount
igg
antibodi
manag
itp
increas
platelet
count
prevent
andor
control
bleed
allow
patient
undergo
surgeri
ivig
use
prevent
bacteri
infect
patient
hypogammaglobulinemia
andor
recurr
bacteri
infect
associ
bcell
chronic
lymphocyt
leukemia
ivig
use
conjunct
aspirin
therapi
initi
treatment
acut
phase
kawasaki
diseas
ivig
also
use
treat
chronic
inflammatori
demyelin
polyneuropathi
improv
neuromuscular
disabl
impair
mainten
therapi
prevent
relaps
furthermor
ivig
use
mainten
treatment
improv
muscl
strength
disabl
adult
multifoc
motor
neuropathi
advers
reaction
approxim
infus
associ
advers
reaction
includ
infus
site
erythema
pain
swell
pruritu
heat
phlebiti
eczema
fever
chill
myalgia
malais
flush
rash
diaphoresi
pruritu
bronchospasm
chest
pain
back
pain
extrem
pain
dizzi
blood
pressur
chang
nausea
vomit
headach
late
centuri
monoclon
antibodi
develop
first
monoclon
antibodi
mab
xenograph
sourc
wrought
problem
immunogen
earli
mab
gain
favor
chimer
took
pace
two
mab
approv
treat
one
respiratori
syncyti
viru
certain
breast
cancer
develop
human
gener
fulli
human
mab
led
evolut
therapi
util
agent
mab
research
approv
treat
multitud
diseas
includ
oncolog
inflammatori
autoimmun
cardiovascular
respiratori
neurolog
allerg
benign
hematolog
infecti
orthoped
coagulopath
metabol
indic
decreas
diseas
morbid
diminut
pain
modifi
diseas
progress
ie
macular
degener
diabet
potenti
alter
anatom
develop
section
chapter
review
histori
use
passiv
monospecif
antibodi
therapi
mechan
action
pharmacologictherapeut
classif
particular
medic
indic
advers
reaction
potenti
futur
use
medic
depend
antigen
target
antibodi
multipl
event
set
action
immunolog
chang
occur
specif
antigen
present
effici
effector
cell
action
creat
decreas
inflammatori
allerg
respons
effect
gener
antibodydepend
cytotox
adcc
complementdepend
cytotox
cdc
action
block
receptor
interact
ligand
either
bind
ligand
cognat
receptor
ie
allow
activ
nk
cell
interact
may
also
directli
caus
initi
program
cell
death
apoptosi
cessat
growthreplicationprolifer
lead
chang
metabol
moreov
also
antibodi
infecti
agent
prevent
cell
adhes
entri
spread
replic
contagion
antibodi
may
also
direct
toxin
lead
variou
method
inactiv
depend
mode
action
mab
associ
myriad
side
effect
associ
immunogen
caus
decreas
effect
antineoplast
antibodi
associ
tumor
lysi
syndrom
similarli
reactiv
underli
infect
occur
lead
progress
multifoc
leukoencephalopathi
hbv
fungal
parasit
tuberculosi
infect
advers
reaction
includ
limit
initi
autoimmun
disord
increas
risk
malign
cardiac
arrhythmia
anginaischemia
cytopenia
hemorrhag
allerg
reaction
includ
anaphylaxi
embryoefet
toxic
cross
placent
barrier
even
death
malign
caus
infecti
agent
toxin
genet
mutat
chang
control
growth
prolifer
program
cell
death
histor
treat
varieti
radiat
therapi
erad
malign
cell
chemotherapeut
agent
enhanc
matur
decreas
prolifer
caus
destruct
cancer
cell
case
intens
highdos
chemotherapi
use
caus
cancer
remiss
stem
cell
transplant
subsequ
rescu
passiv
antibodi
therapi
may
replac
addit
pharmacolog
therapi
increas
chanc
complet
remiss
prolong
diseasefre
surviv
overal
surviv
rituximab
rituxan
chimer
murinehuman
mab
bind
human
blymphocyterestrict
differenti
antigen
control
differenti
possibl
calcium
ion
channel
mechan
action
entir
clear
may
involv
cdc
adcc
mani
studi
shown
antibodi
addit
benefit
standard
chemotherapi
alon
antibodi
approv
fda
treat
chronic
lymphocyt
leukemia
cll
sinc
nowaday
medic
often
combin
ibritumomab
treat
cll
discuss
nonhodgkin
lymphoma
alemtuzumab
campath
bind
human
rat
mab
bind
receptor
b
cell
well
macrophag
nk
cell
neutrophil
lead
cdc
adcc
result
cytopenia
lead
sever
immunocompromis
state
alemtuzumab
fda
approv
singl
agent
treatment
bcell
cll
ofatumumab
ocrevu
human
mab
cdc
bind
near
cellular
membran
phase
ii
studi
agent
object
respons
rate
orr
use
alon
chop
therapi
orr
complet
remiss
cr
wherea
phase
iii
trial
mab
show
orr
rituximab
relaps
medic
approv
fda
treat
cll
monalizumab
human
mab
bind
inhibitori
signal
receptor
transmitt
nk
cell
monalizumab
demonstr
blockad
restor
abil
nk
cell
lyse
b
cell
vitro
addit
mab
shown
benefit
murin
model
ongo
phase
iii
studi
complet
otlertuzumab
human
mab
fragment
igg
fab
specif
induc
adcc
caspaseindepend
apoptosi
phase
ii
studi
better
progressionfre
surviv
pf
orr
observ
use
bendamustin
compar
bendamustin
use
alon
urelumab
human
mab
specif
immun
checkpoint
inhibitor
antibodi
complet
safeti
phase
dose
trial
higher
dose
lead
signific
hepatotox
safe
dose
establish
clinic
phase
ii
studi
complet
ulocuplumab
human
mab
specif
vitro
studi
show
apoptot
effect
via
product
oxygen
speci
associ
better
caspas
activ
phase
studi
complet
manuscript
found
review
medic
present
phase
ii
trial
acut
myelocyt
leukemia
aml
complet
monoclon
antibodi
demonstr
benefit
clinic
trial
cll
includ
apolizumab
dacetuzumab
gomiliximab
aka
lumiliximab
acut
myelocyt
leukemia
aml
lead
caus
leukem
mortal
unit
state
us
last
year
therapi
chang
significantli
diseas
novel
therapi
develop
last
decad
show
tempor
success
show
brighter
tomorrow
bispecif
tcell
engag
bite
antibodi
specif
mab
current
clinic
trial
complet
treatment
aml
bite
antibodi
stimul
adcc
via
cell
presenc
antigen
target
cell
interest
vitro
studi
shown
effect
lysi
aml
cell
anim
studi
demonstr
signific
decreas
tumor
burden
antibodi
complex
dna
monoalkyl
agent
vitro
studi
show
potenc
aml
cell
normal
myeloid
progenitor
cell
anim
model
excel
respons
rate
tumor
cell
ongo
clinic
trial
complet
talacotuzumab
human
monoclon
antibodi
specif
interleukin
il
receptor
subunita
growth
differenti
receptor
antibodi
induc
adcc
vitro
anim
model
phase
iii
clinic
trial
reportedli
complet
publish
result
forthcom
samalizumab
human
mab
specif
glycoprotein
phase
ii
trial
complet
ficlatuzumab
human
mab
phase
trial
treat
refractoryrelaps
aml
complet
mab
demonstr
benefit
clinic
trial
withdrawn
follow
postmarket
aml
includ
gemtuzumab
ozogamicin
fda
approv
withdrawn
secondari
venoocclus
diseas
lintuzumab
ad
benefit
standard
chemotherapi
daratumumab
darzalex
human
mab
specif
function
reportedli
includ
receptormedi
adhes
signal
event
well
import
bifunct
ectoenzymat
activ
contribut
intracellular
calcium
mobil
mab
mechan
action
thought
induc
cdc
adcc
antibodydepend
cellular
phagocytosi
apoptosi
medic
use
treat
refractori
recurr
multipl
myeloma
silutuximab
sylvant
chimer
mab
specif
medic
fda
approv
multicentr
castleman
diseas
mcd
hiv
neg
neg
ongo
studi
phase
ii
clinic
trial
complet
bcell
acut
lymphoblast
leukemia
bcell
blinatumomab
blincyto
mous
doubl
heavychain
fragment
murin
scfv
kappa
e
heavi
e
scfv
heavi
e
kappa
specif
known
bite
mab
mode
action
direct
effector
memori
cell
target
cell
lead
tcell
activ
bcell
apoptosi
biolog
use
treat
relapsedrefractori
cell
phase
iii
trial
eventfre
surviv
almost
tripl
durat
remiss
almost
doubl
hodgkin
lymphoma
rare
malign
affect
young
adult
peak
incid
patient
year
old
patient
develop
relaps
diseas
brentuximab
vedotin
adcentrix
chimer
human
mab
drug
conjug
mab
linker
payload
cleavag
linker
monomethyl
auristatin
e
mmae
specif
cell
membran
protein
tumor
necrosi
factor
receptor
superfamili
member
mmae
microtubuledisrupt
agent
combin
mab
drug
conjug
disrupt
intracellular
microtubul
network
caus
cell
cycl
arrest
stage
apoptosi
medic
pf
month
mab
look
futur
includ
camidanlumab
tesirin
human
mab
mab
specif
receptor
alpha
subunit
drug
conjug
drug
releas
intracellularli
caus
dna
interstrand
crosslink
mab
phase
studi
complet
hodgkin
nonhodgkin
tand
bcell
lymphoma
addit
clinic
phase
studi
multipl
solid
tumor
complet
agent
abandon
found
benefici
includ
apolizumab
denintuzumab
mafodotin
iratumumab
lucatumumab
anaplast
larg
cell
lymphoma
brentuximab
vedotin
adcentrix
fdaapprov
medic
patient
refractori
relaps
anaplast
larg
cell
lymphoma
achiev
cr
mab
os
pf
year
median
respons
durat
reach
time
public
atezolizumab
tecentriq
fcgr
bindingedefici
fulli
human
mab
mab
bind
program
death
ligand
prevent
interact
receptor
costimulatori
cellsurfac
protein
revers
tcell
suppress
activ
potenti
stimul
longterm
respons
develop
new
immun
via
prime
activ
cell
lymph
node
lack
fcgr
bind
decreas
adcc
cell
enabl
tumorspecif
cell
remain
activ
medic
approv
fda
treat
tripl
neg
estrogen
receptor
progesteron
receptor
human
epiderm
growth
factor
unresect
metastat
breast
cancer
colorect
cancer
bevacizumab
avastin
human
mab
specif
vascular
endotheli
growth
factora
vegfa
act
inhibitor
angiogenesi
fda
approv
treatment
colorect
cancer
recent
approv
multipl
cancer
includ
ovarian
fallopian
cancer
renal
cell
carcinoma
recurr
glioblastoma
multiform
gbm
urotheli
carcinoma
atezolizumab
tecentriq
fda
approv
singl
agent
urotheli
carcinoma
patient
diseas
progress
despit
chemotherapi
treatment
nonsmal
cell
lung
cancer
atezolizumab
tecentriq
fda
approv
singl
agent
nonsmal
cell
lung
cancer
nsclc
bevacizumab
avastin
fda
approv
treatment
local
advanc
recurr
metastat
nonsquam
nsclc
nivolumab
opdivo
fdaapprov
human
mab
immunoglobulin
block
prevent
interact
ligand
use
treat
rcc
nsclc
hodgkin
lymphoma
melanoma
small
cell
lung
cancer
colorect
cancer
squamou
cell
carcinoma
head
neck
phase
iii
clinic
trial
nivolumab
perform
better
docetaxel
treatment
nsclc
ovariancerv
fallopian
cancer
bevacizumab
avastin
fda
approv
treatment
local
advanc
recurr
metastat
ovarian
cervic
fallopian
cancer
treatment
chemotherapi
regimen
surgeri
merkel
cell
carcinoma
rare
aggress
cutan
malign
caus
infect
polyoma
viru
exposur
ultraviolet
radiat
cancer
classic
treat
chemotherapeut
agent
lead
rare
durabl
respons
avelumab
bavencio
fulli
human
mab
specif
mab
approv
fda
treatment
merkel
cell
carcinoma
treatment
mab
increas
respons
rate
extend
durabl
respons
time
approxim
five
time
mab
clinic
trial
treat
solid
tumor
includ
limit
hepatocellular
ovarian
esophagogastr
colorect
nsclc
testicular
urotheli
adrenocort
carcinoma
neuroblastoma
neuroblastoma
aggress
tumor
children
surviv
treatment
classic
highdos
intens
chemotherapi
myeloabl
chemotherapi
stem
cell
rescu
andor
irradi
therapi
dinutuximab
unituxin
chimer
mab
specif
gangliosid
mechan
action
via
cdc
adcc
mab
use
patient
least
partial
respons
classic
therapi
glioblastoma
multiform
gbm
common
malign
primari
brain
tumor
adult
diseas
remain
incur
bevacizumab
avastin
fda
approv
treatment
recurr
gbm
salvag
therapi
medic
chemotherapi
increas
overal
surviv
month
singl
agent
effect
relatlimab
human
mab
specif
lymphocyt
activ
gene
phase
clinic
trial
complet
treatment
gbm
tanibirumab
aka
olinvacimab
human
mab
specif
vascular
endotheli
growth
factor
phase
ii
studi
treat
gbm
complet
catumaxomab
removab
trifunct
ratmurin
hybrid
antibodi
catumaxomab
consist
one
half
one
heavi
chain
one
light
chain
antiepitheli
cell
adhes
molecul
antiepcam
antibodi
onehalf
antibodi
molecul
catumaxomab
bind
epcam
addit
fcregion
bind
fc
receptor
accessori
cell
antibodi
led
call
drug
trifunct
antibodi
antibodi
mechan
action
adcc
approv
use
europ
malign
ascit
ovarian
gastric
colon
pancreat
breast
endometri
carcinoma
pend
review
approv
fda
cutan
squamou
cell
carcinoma
cemiplimab
libtayo
human
mab
treatment
cutan
squamou
cell
carcinoma
cscc
metastat
local
advanc
amen
surgeri
cscc
second
basal
cell
carcinoma
common
skin
cancer
surgic
intervent
possibl
patient
mab
offer
treatment
less
morbid
palli
radiat
surgeri
give
orr
otherwis
untreat
patient
mani
addit
phase
ii
studi
involv
mab
complet
inflammatori
bowel
diseas
ibd
pathophysiolog
remain
unknown
may
genet
infecti
autoimmun
origin
includ
cellmedi
immun
diseas
may
classifi
ulcer
coliti
uc
isol
colon
crohn
diseas
primarili
found
colon
may
involv
entir
gastrointestin
tract
longstand
activ
diseas
malign
much
frequent
uc
crohn
diseas
mild
uc
treat
antiinflammatori
agent
sulfasalazin
glucocorticosteroid
sever
diseas
highdos
steroid
may
use
maintain
diseas
quiescent
lowdos
steroid
keep
diseas
remiss
lowdos
chemotherapeut
agent
immunosuppress
agent
may
also
ad
dose
corticosteroid
high
maintain
remiss
surgeri
may
necessari
control
diseas
crohn
diseas
medic
therapi
usual
less
success
manag
diseas
surgeri
may
necessari
cur
uc
diseas
process
passiv
antibodi
therapi
may
offer
control
diseas
possibl
complet
remiss
mucos
damag
adalimumab
two
formul
humira
amjevita
recombin
human
mab
specif
tumor
necrosi
factor
alpha
tnfa
form
fda
approv
treat
crohn
diseas
well
multipl
type
rheumatoid
arthriti
crohn
diseas
medic
decreas
sign
symptom
diseas
abl
induc
clinic
remiss
certolizumab
cimzia
recombin
human
fragment
tnfa
target
fda
approv
crohn
diseas
rheumatoid
arthriti
vedolizumab
entyvio
human
mab
select
integrin
fda
approv
treatment
crohn
diseas
mab
mode
action
select
block
traffick
memori
cell
inflam
gut
tissu
inhibit
addressin
cell
adhes
interact
intestin
vasculatur
medic
shown
good
safeti
profil
case
promyelocyt
leukemia
pml
increas
risk
infect
malign
compar
classic
treat
ibd
low
incid
infusionrel
reaction
medic
also
fda
approv
uc
infliximab
remicad
inflectra
remsira
chimer
mab
specif
tnfa
fda
approv
ibd
multipl
inflammatori
arthrit
diseas
medic
allow
steroidfre
remiss
within
month
start
therapi
natalizumab
tysabri
human
mab
select
l
selectin
subunit
integrin
leukocyt
neutrophil
mab
fda
approv
crohn
diseas
multipl
sclerosi
medic
effect
induct
clinic
remiss
moderatetosever
crohn
diseas
medic
risk
pml
mab
studi
crohn
diseas
yet
approv
fda
includ
ustekinumab
brazikumab
etrolizumab
risankizumab
ontamalimab
contrast
mab
studi
benefici
crohn
diseas
includ
andecaliximab
eldelumab
fontolizumab
refer
mab
studi
uc
yet
approv
fda
includ
bimekizumab
etrolizumab
golimumab
mirikizumab
ravagalimab
sacituzumab
govitecan
ontamalimab
vatelizumab
refer
autoimmun
diseas
affect
mani
organ
tissu
includ
liver
gall
bladder
pancrea
b
islet
cell
diabet
mellitu
nerv
junction
myasthenia
gravi
thyroid
bone
joint
blood
vessel
multiorgan
system
system
lupu
erythematosu
sle
autoimmun
arthriti
multipl
type
includ
psoriat
sclerosi
rheumatoid
arthriti
ra
sle
mani
diseas
mediat
antibodi
cellular
autoimmun
ultim
appear
secondari
underli
abnorm
tcell
immuneregulatori
control
diseas
process
histor
control
antiinflammatori
agent
immunosuppressiveimmunomodulatori
agent
lowdos
chemotherapi
result
hormon
defici
supplement
hormon
deplet
diseas
process
hope
passiv
antibodi
therapi
mitig
sequela
inflammatori
process
psoriasi
affect
world
popul
inflammatori
skin
diseas
brodalumab
siliz
human
mab
specif
receptor
fda
approv
treatment
plaqu
psoriasi
mechan
action
inhibit
heterodim
cytokineinduc
respons
includ
releas
proinflammatori
cytokin
compar
ustekinumab
respons
rate
nearli
doubl
brodalumab
phase
ii
phase
iii
trial
induct
mainten
therapi
therapi
current
also
approv
studi
treatment
diseas
includ
bermekimab
xilonix
bimekizumab
briakinumab
certolizumab
pegol
cimzia
etanercept
enbrel
infliximab
remicad
inflectra
remsima
itolizumab
alzumab
adalimumab
humira
amjevita
ustekinumab
stelara
secukinumab
cosentyx
guselkumab
tremfya
tildrakizumab
ilumya
ilumetri
risankizumab
mirikizumab
namilumab
netakimab
vunakizumab
refer
tabl
withdrawn
market
ineffect
treat
psoriasi
includ
efalizumab
raptiva
fezakinumab
bleselumab
teplizumab
alaala
refer
abatacept
orencia
recombin
solubl
fusion
protein
extracellular
domain
human
cytotox
tlymphocyteassoci
antigen
link
modifi
fc
portion
human
mechan
action
select
costimul
modul
inhibit
lymphocyt
activ
bind
therebi
block
interact
interact
provid
costimulatori
signal
necessari
full
activ
lymphocyt
medic
fda
approv
juvenil
idiopath
arthriti
jia
adult
ra
certolizumab
pegol
alon
methotrex
improv
qualiti
life
ra
may
caus
diseas
remiss
reduc
joint
damag
certolizumab
pegoli
also
approv
use
ankylos
spondyl
belimumab
benlysta
human
mab
bind
bcell
activ
factor
act
blymphocyt
stimulatorspecif
inhibitor
approv
fda
treatment
adult
patient
activ
autoantibodyposit
sle
receiv
standard
therapi
medic
also
decreas
episod
frequenc
lupu
nephriti
despit
mark
improv
surviv
cardiovascular
diseas
ill
remain
number
one
caus
mortal
us
process
caus
injuri
endothelium
blood
vessel
heart
secondari
toxin
accumul
cholesterol
chronic
lowgrad
inflamm
treatment
prevent
primarili
actual
injuri
follow
injuri
therapi
involv
chang
behavior
diet
exercis
cessat
tobacco
use
pharmacolog
control
contribut
underli
ill
hypercholesterolemia
hypertens
diabet
type
ii
diminish
injuri
thrombolyt
stent
vasodil
supplement
oxygen
control
sequela
infarct
cardiac
dysfunctionfailur
passiv
antibodi
therapi
tri
decreas
effect
contribut
factor
atherosclerot
plaqu
format
abciximab
reopro
chimer
recombin
monoclon
fragment
fab
specif
platelet
glycoprotein
iibiiia
receptor
intergrin
aiib
prevent
platelet
bind
fibrinogen
mab
also
prevent
coagul
factor
xiii
bind
platelet
allow
stabil
clot
easili
lyse
fc
portion
antibodi
remov
decreas
thrombocytopenia
antibodi
use
highrisk
coronari
intervent
prevent
clot
format
cardiac
ischemia
alirocumab
praluent
human
mab
specif
proprotein
convertas
subtilisinkexin
type
medic
use
control
cholesterol
level
patient
high
risk
cardiovascular
event
patient
famili
hypercholesterolemia
control
agent
evolocumab
repatha
human
mab
fda
approv
treatment
hypercholesterolemia
patient
famili
hypercholesterolemia
histori
cardiovascular
diseas
mab
specif
medic
reduc
lowdens
lipoprotein
ldl
cholesterol
level
even
statin
therapi
hazard
ratio
primari
secondari
endpoint
less
one
fewer
cardiovascularrel
death
infarct
stroke
futur
watch
frovocimab
human
mab
specif
complet
phase
ii
trial
reduct
ldl
cholesterol
level
phase
iii
studi
yet
perform
addit
antibodi
lodelcizumab
human
mab
howev
studi
found
clinicaltrialsgov
pubm
search
bococizumab
human
mab
phase
iii
trial
discontinu
secondari
primari
endpoint
achiev
besid
autoimmun
malign
diseas
neurolog
system
also
diseas
central
nervou
system
classifi
degen
diseas
includ
supranuclear
palsi
snp
alzheim
parkinson
alzheim
like
common
caus
dementia
first
describ
diseas
may
depict
presenil
senil
dementia
progress
similar
rate
matter
age
onset
diseas
genet
predisposit
caus
occur
younger
age
group
histolog
chang
includ
diffus
plaqu
contain
amyloid
neurofibrillari
plaqu
neuron
loss
especi
hippocampu
tempor
region
medic
manag
may
revers
symptom
prevent
diseas
progress
parkinson
mainli
sporad
degen
diseas
gradual
progress
cours
mainli
affect
motor
function
memori
first
describ
diseas
substantia
nigra
character
loss
melanin
contain
nerv
cell
eosinophil
intracytoplasm
inclus
asid
emot
support
physic
therapi
medic
therapi
use
decreas
tremor
includ
anticholinerg
drug
tremor
onset
beta
blocker
intent
tremor
levodopa
postur
imbal
akinesia
deep
brain
stimul
also
use
treat
symptom
later
diseas
progress
snp
start
age
rang
parkinson
middl
later
life
first
describ
disturb
gait
balanc
secondari
rigid
trunk
muscl
loss
neuron
gliosi
seen
midbrain
medic
treatment
rel
unsuccess
multipl
sclerosi
demyelin
diseas
often
seen
young
adult
clinic
manifest
divers
progress
chronic
acut
remit
relaps
medic
therapeut
plasma
exchang
use
treat
debilit
diseas
limit
efficaci
clinic
trial
ongo
look
mab
therapi
treatment
four
neurolog
degen
diseas
alemtuzumab
lemtrada
human
mab
target
deplet
lymphocyt
b
cell
report
earlier
fda
approv
treatment
acut
relaps
remit
multipl
sclerosi
ocrelizumab
ocrevu
human
mab
specif
bcell
membran
protein
phase
ii
trial
decreas
brain
lesion
imag
decreas
rate
disabl
declin
primari
progress
multipl
sclerosi
natalizumab
tysabri
monoclon
human
antibodi
specif
cell
adhes
molecul
fda
approv
relaps
multipl
sclerosi
mab
watch
futur
clinic
trial
includ
anifrolumab
human
monoclon
antibodi
phase
trial
elezanumab
human
mab
specif
repuls
guidanc
molecul
famili
membera
phase
ii
trial
complet
final
inebilizumab
human
monoclon
antibodi
specif
bcell
lymphocyt
protein
mab
mechan
action
via
adcc
complet
phase
trial
good
safeti
profil
respons
decreas
lesion
seen
contrast
enhanc
magnet
reson
imag
otilimabi
human
mab
complet
phase
studi
good
safeti
profil
target
granulocytemacrophag
colonystimul
factor
ublituximab
phase
ii
clinic
studi
complet
phase
iii
studi
schedul
complet
mab
chimer
mab
specif
addit
mab
seriou
advers
effect
daclizumab
human
monoclon
specif
ineffect
opicinumab
human
mab
specif
leucinerich
repeat
immunoglobulin
domain
contain
neurit
outgrowth
inhibitor
receptor
interact
phase
ii
trial
benefici
placebo
treat
optic
neuriti
multipl
sclerosi
patient
alzheim
diseas
aducanumab
human
mab
specif
bamyloid
nterminu
solubl
oligom
insolubl
fiber
phase
iii
clinic
trial
ongo
sinc
human
mab
specif
bamyloid
fibrillari
solubl
b
amyloid
phase
iib
clinic
studi
sinc
gosuranemab
human
mab
specif
tau
protein
clinic
trial
treat
alzheim
diseas
schedul
complet
gosuranemab
also
phase
studi
treat
progress
suranuclear
palsi
complet
crenezumab
human
mab
specif
bamyloid
phase
iii
studi
schedul
complet
gantenerumab
human
mab
target
bamyloid
mab
initi
phase
iii
studi
found
ineffect
ongo
phase
iiiii
trial
current
place
higher
dose
clinic
popul
peopl
autosom
domin
form
alzheim
diseas
solanezumab
human
mab
specif
beta
amyloid
initi
phase
iii
trial
discontinu
lack
efficaci
prevent
alzheim
diseas
ongo
phase
iii
trial
place
secondari
prevent
diseas
complet
mab
antibodi
studi
ineffect
includ
bapineuzumab
gantenerumab
ponezumab
prasinezumab
human
mab
specif
asynuclein
mab
phase
ii
clinic
trial
treat
parkinson
complet
allerg
reaction
develop
immunolog
stimul
ige
antibodi
follow
interact
allergen
mast
cell
effect
local
dermat
system
respiratori
cardiovascular
gastrointestin
treatment
either
avoid
allergen
support
therapi
acut
allerg
reaction
includ
pharmacolog
treatment
type
histamin
blocker
glucocorticosteroid
lifethreaten
epinephrin
passiv
antibodi
therapi
studi
approv
curtail
sever
reaction
asthma
affect
million
individu
us
asthma
patient
sever
diseas
may
uncontrol
despit
high
dose
standardofcar
asthma
medic
requir
addit
use
chronic
oral
corticosteroid
benralizumab
fensenra
human
mab
specif
mab
approv
treat
sever
asthma
eosinophil
subtyp
age
older
mechan
action
decreas
number
eosinophil
via
adcc
basophil
also
deplet
dupilumab
dupix
human
monoclon
antibodi
specif
receptor
subunitalpha
approv
treat
sever
atop
dermat
adult
coagulopathi
usual
either
autoimmun
genet
factor
viii
defici
recombin
factor
viii
use
replac
lack
protein
howev
patient
may
develop
antibodi
factor
viii
lead
high
titer
inhibitor
furthermor
patient
without
defici
may
also
develop
autoantibodi
factor
viii
de
novo
lead
coagulopathi
factor
combin
well
recombin
activ
factor
creat
overcom
inhibitori
antibodi
mab
bispecif
bind
also
research
anoth
avenu
treatment
itp
lead
critic
low
platelet
level
increas
risk
sever
bleed
itp
occur
adult
pediatr
set
consid
autoimmun
diseas
typic
treat
steroid
ivig
addit
mention
earlier
rhd
patient
benefit
polyclon
medic
direct
antigen
recent
mab
treat
diseas
develop
discuss
next
thrombot
thrombocytopen
purpura
ttp
blood
disord
lead
bleed
develop
diffus
thrombi
small
blood
vessel
often
disord
secondari
autoimmun
inhibitori
antibodi
disintegrin
metalloproteinas
thrombospondin
type
motif
known
acquir
ttp
inhibit
zinc
contain
metalloproteas
lead
lack
cleavag
larg
multim
von
willebrand
factor
vwf
larg
vwf
multim
easili
bind
platelet
result
platelet
clot
small
blood
vessel
rare
disord
secondari
inherit
defici
patient
popul
congenit
defici
manag
transfus
ffp
replac
defici
enzym
acquir
ttp
typic
treat
therapeut
plasma
exchang
tpe
treatment
modal
remov
inhibitori
antibodi
ultralarg
vwf
multim
similarli
tpe
replet
miss
enzym
immunosuppress
agent
may
ad
tpe
effect
mab
prevent
interact
vwf
platelet
recent
approv
use
treat
disord
caplacizumabyhdp
cablivi
human
singlevariabledomain
immunoglobulin
nanobodi
inhibit
interact
ultralarg
vwf
multim
platelet
direct
vwf
induc
faster
respons
therapi
tpe
decreas
relaps
continu
use
tpe
medic
use
posttp
treatment
immunolog
evid
diseas
control
prevent
relaps
medic
fda
approv
use
ttp
atyp
hemolyt
urem
syndrom
ahu
disord
complement
system
due
uncontrol
activ
disord
present
thrombocytopenia
thrombi
renal
dysfunct
histor
ill
treat
tpe
howev
endstag
renal
failur
occur
patient
mortal
subsequ
relaps
increas
incid
renal
failur
two
monoclon
antibodi
approv
treatment
ahu
refer
sickl
cell
diseas
one
frequent
complic
pain
crise
usual
treat
analges
oxygen
hydrat
transfus
simpl
exchang
monoclon
antibodi
develop
treat
pain
crise
sickl
cell
patient
adult
pediatr
popul
crizanlizumab
human
mab
specif
selectin
p
one
phase
ii
trial
complet
three
addit
phase
ii
studi
complet
treat
vasoocclus
pain
crisi
medic
may
fda
review
earli
infect
antimicrobi
histor
develop
varieti
viral
bacteri
fungal
parasit
infect
pharmaceut
target
differ
human
cell
particular
organ
cell
wall
membran
structur
genet
makeup
transcript
translat
genet
materi
metabol
pathway
often
organ
develop
resist
entir
categori
medic
earlier
chapter
passiv
polyclon
antibodi
discuss
treatment
infecti
agent
discuss
research
monoclon
therapi
pathogen
microorgan
enterocol
clostridium
difficil
commun
hospit
acquir
infect
increas
morbid
mortal
acquir
treatment
support
fecal
transplant
antibiot
bezlotoxumab
zinplava
human
mab
specif
clostridium
difficil
b
toxin
use
treat
pseudomembran
coliti
prevent
c
difficil
reinfect
actoxumab
monoclon
antibodi
c
difficil
toxin
shown
clinic
signific
respiratori
syncyti
viru
rsv
infect
almost
children
year
old
pose
extra
risk
preterm
infant
support
therapi
rsvig
ivig
antivir
therapi
use
mitig
sequela
infect
optim
respons
yet
seen
vaccin
yet
develop
infect
recent
monoclon
antibodi
fda
approv
undergo
preclin
trial
treat
infecti
process
includ
palivizumab
nirsevimab
benefici
safe
use
rsv
motavizumab
suptavumab
influenza
worldwid
respiratori
infecti
problem
cyclic
epidem
yearli
support
therapi
yearli
vaccin
antivir
use
decreas
morbid
mortal
caus
sometim
virul
pathogen
polyclon
monoclon
therapi
evalu
better
treat
infect
mab
preclin
trial
includ
diridavumab
firivumab
gedivumab
lesofavumab
navivumab
rabi
devast
viral
infect
swift
mortal
treat
quickli
initi
exposur
vaccin
usual
react
slowli
combin
polyclon
ivig
infus
monoclon
therapi
previous
studi
usual
viru
mutat
quickli
infect
control
recent
clinic
trial
cocktail
mab
tri
close
mimic
benefit
polyclon
therapi
mab
includ
foravirumab
rafivirumab
rmab
hbv
one
common
infect
world
even
though
antivir
avail
effect
recent
wide
use
infant
popul
high
risk
individu
mab
treat
infect
investig
includ
libivirumab
mab
found
effect
tuvirumab
ebola
rel
rare
devast
hemorrhag
infect
care
support
variou
studi
perform
preventmitig
diseas
vaccin
develop
well
passiv
polyclon
therapi
mab
therapi
develop
studi
includ
porgaviximab
cosfroviximab
larcaviximab
bacteri
fungal
viral
antiinfecti
agent
inform
may
found
solid
organ
transplant
cellular
humor
immun
develop
transplant
lead
acut
chronic
reject
addit
complic
stem
cell
transplant
sever
gvhd
past
transplant
complic
treat
highdos
glucocorticosteroid
immunosuppress
medic
chemotherapeut
agent
ivig
tcell
lymphocyt
specif
immunoglobulin
recent
mab
ad
armamentarium
better
control
advers
reaction
transplant
basiliximab
simulect
chimer
mab
specif
fdaapprov
indic
medic
prophylaxi
acut
reject
renal
transplant
patient
multipl
ongo
studi
biolog
organ
transplant
includ
liver
lung
heart
well
inflammatoryimmunolog
diseas
gvhd
follow
stem
cell
transplant
ulcer
coliti
uveiti
belatacept
nulojix
solubl
fusion
protein
consist
modifi
extracellular
domain
fuse
fc
domain
recombin
human
mab
mab
select
inhibit
tcell
activ
costimul
blockad
bind
block
via
tighter
bind
parent
antibodi
abatacept
refer
hypercholesterolemia
associ
increas
risk
cardiovascular
diseaseatherosclerosi
secondari
inherit
dietari
etiolog
diet
exercis
use
treat
mild
form
disord
medic
nicotin
acid
fibrat
bile
acid
bind
resin
reductas
inhibitor
use
sever
form
disord
phase
iii
studi
complet
monoclon
antibodi
patient
refractori
previous
mention
form
therapi
burosumab
crysvita
human
mab
specif
phosphatur
hormon
fibroblast
growth
factor
fgf
hormon
regul
phosphat
vitamin
homeostasi
inhibit
enzym
stimul
therebi
reduc
circul
level
oh
activ
metabolit
vitamin
medic
fda
approv
treatment
xlink
hypophosphatem
ricket
osteoporosi
denosumab
prolia
fdaapprov
human
mab
receptor
activ
nuclear
factor
kb
ligand
inhibit
develop
activ
osteoclast
prolia
medic
use
prevent
treat
osteoporosi
women
medic
trade
name
xgeva
also
use
prevent
skeletalrel
event
adult
bone
metastasi
breast
prostat
cancer
multipl
myeloma
endocrin
disord
diabet
may
classifi
primari
secondari
chapter
mainli
interest
insulindepend
type
insulinindepend
type
type
ii
type
diabet
mellitu
gener
secondari
loss
b
cell
islet
langerhan
subsequ
loss
insulin
product
type
ii
typic
secondari
decreas
sensit
effect
insulin
type
insulin
replac
exogen
depend
glucos
level
type
ii
medic
given
stimul
islet
cell
produc
insulin
mab
develop
potenti
mitig
autoimmun
process
lead
type
diabet
mellitu
sequela
renal
failur
often
seen
diseas
type
ii
mab
investig
potenti
decreas
bodi
mass
index
thu
decreas
diseas
sever
refer
agerel
macular
degener
amd
lead
irrevers
caus
visual
loss
affect
elderli
two
form
includ
dri
form
deposit
macula
wet
form
involv
abnorm
growth
blood
vessel
wet
form
even
though
less
frequent
associ
sever
visual
acuiti
loss
antiangiogenes
drug
laser
treatment
use
slow
progress
even
partial
revers
visual
loss
trial
complet
other
ongo
use
mab
treat
wet
form
amd
brolucizumab
found
good
better
aflibercept
phase
iii
clinic
trial
cryopyrinassoci
period
syndrom
includ
famili
cold
autoinflammatori
syndrom
mucklewel
syndrom
tumor
necrosi
factor
receptorassoci
period
syndrom
trap
hyperimmunoglobulin
syndrom
hid
mevalon
kinas
defici
famili
mediterranean
fever
fmf
may
also
respond
canakinumab
passiv
antibodi
therapi
continu
use
clinic
whether
polyclon
monoclon
therapi
implement
increas
util
classic
polyclon
antibodi
prepar
continu
especi
realm
infect
past
year
monoclon
therapi
evolv
revolution
treatment
mani
area
target
identifi
modifi
diseas
patholog
matter
genr
continu
get
better
handl
morbid
mortal
learn
target
import
put
portion
target
mediat
effect
intend
modifi
also
import
importantli
modif
antibodi
compat
immun
system
decreas
rapid
clearanc
also
allow
consist
therapi
also
mani
target
yet
discov
develop
canon
winglessintegr
wnt
signal
receptor
famili
import
multitud
diseas
limit
hereditari
colorect
cancer
variou
type
sporad
cancer
intellectu
disabl
syndrom
alzheim
diseas
bipolar
disord
bone
diseas
vascular
diseas
one
monoclon
antibodi
rosmantuzumab
human
mab
phase
trial
treat
colorect
cancer
diseas
process
yet
find
optim
therapi
alzheim
advanc
fuller
therapeut
benefit
futur
wide
open
newer
class
pharmaceut
continu
develop
full
fruition
